Pfizer Lifts Full-Year Revenue Guidance After Q2 Results Beat Expectations
Pfizer’s second-quarter results topped internal expectations, leading the company to raise its full-year revenue guidance and emphasize progress in key non-COVID therapies. Valuation discussions frame the stock as potentially undervalued, while noting uncertainty around patent expiries and drug pricing rules that could affect margins.